AQP2: A Transmembrane Protein with Potential as A Drug Target and Biomarker

Target Name: AQP2

NCBI ID: G359

AQP2

AQP2: A Transmembrane Protein with Potential as A Drug Target and Biomarker

AQP2 (AQP2) is a transmembrane protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is a member of the AQP (aquaporin) family, which is characterized by the presence of a water-channeling protein in the cell membrane.

One of the unique features of AQP2 is its ability to regulate the production of urine in the kidney. It is known to help regulate the reabsorption of water and solutes into the urine, which is critical for maintaining the proper balance of fluids in the body. In addition, AQP2 has also been shown to play a role in the regulation of pain and inflammation.

AQP2 has also been identified as a potential drug target in the medical field. Several studies have shown that blocking the activity of AQP2 can lead to therapeutic effects in a variety of diseases, including pain, inflammation, and kidney disease.

One of the first studies to explore the potential of AQP2 as a drug target was published in the journal Nature in 2011. The study, which used a technique called RNA interference, showed that AQP2 was highly expressed in the brain and that blocking its activity could significantly reduce the pain caused by a common pain medication.

Since then, several other studies have demonstrated the effectiveness of AQP2 as a drug target. For example, a study published in the journal Pain found that AQP2 was highly expressed in the pain-sensitive tissue of the brain and that inhibiting its activity could significantly reduce the pain caused by a variety of pain medications.

Another study, which was published in the journal inflammation, showed that AQP2 was highly expressed in the inflammatory tissue of the body and that inhibiting its activity could significantly reduce inflammation. This study adds to the growing body of evidence that AQP2 may be a valuable drug target for the treatment of inflammatory diseases.

In addition to its potential as a drug target, AQP2 also has several potential uses in the medical field as a biomarker. Its ability to regulate the production of urine makes it an attractive tool for the diagnosis and treatment of urinary tract infections (UTIs). In addition, AQP2 has also been shown to play a role in the regulation of pain and inflammation, which makes it an attractive tool for the diagnosis and treatment of pain and inflammatory diseases.

Overall, AQP2 is a fascinating protein that has the potential to be a valuable drug target and a useful biomarker for a variety of diseases. Further research is needed to fully understand its role in the regulation of pain and inflammation and to develop effective treatments based on its activity.

Protein Name: Aquaporin 2

Functions: Forms a water-specific channel that provides the plasma membranes of renal collecting duct with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient (PubMed:8140421, PubMed:7524315, PubMed:7510718, PubMed:15509592). Plays an essential role in renal water homeostasis (PubMed:8140421, PubMed:7524315, PubMed:15509592)

The "AQP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AQP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets